Da: Majestic Books, Hounslow, Regno Unito
EUR 139,05
Quantità: 3 disponibili
Aggiungi al carrelloCondizione: New.
EUR 157,64
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
Da: Books Puddle, New York, NY, U.S.A.
Condizione: New. 1st edition NO-PA16APR2015-KAP.
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 156,95
Quantità: 3 disponibili
Aggiungi al carrelloCondizione: New.
EUR 158,77
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
Da: Ria Christie Collections, Uxbridge, Regno Unito
EUR 169,32
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. In.
EUR 186,51
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
EUR 186,92
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
Lingua: Inglese
Editore: Elsevier Science Publishing Co Inc, US, 2022
ISBN 10: 0128244852 ISBN 13: 9780128244852
Da: Rarewaves.com USA, London, LONDO, Regno Unito
EUR 211,52
Quantità: Più di 20 disponibili
Aggiungi al carrelloHardback. Condizione: New. Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.
EUR 195,78
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. Overview of the history and development of efforts to pharmacologically inhibit RAS. Discussion of the biochemistry and biology of different RAS mutant proteins and how this might be effectively leveraged in the development of anti-RAS the.
Lingua: Inglese
Editore: Elsevier Science Publishing Co Inc, US, 2022
ISBN 10: 0128244852 ISBN 13: 9780128244852
Da: Rarewaves.com UK, London, Regno Unito
EUR 200,89
Quantità: Più di 20 disponibili
Aggiungi al carrelloHardback. Condizione: New. Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.
Da: Brook Bookstore On Demand, Napoli, NA, Italia
EUR 120,14
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: new. Questo è un articolo print on demand.
Lingua: Inglese
Editore: Elsevier Science & Technology, Academic Press, 2022
ISBN 10: 0128244852 ISBN 13: 9780128244852
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
EUR 122,00
Quantità: 2 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once 'undruggable? RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers. Englisch.
Da: Revaluation Books, Exeter, Regno Unito
EUR 157,54
Quantità: 2 disponibili
Aggiungi al carrelloHardcover. Condizione: Brand New. 1st edition. 341 pages. 9.25x6.25x1.00 inches. In Stock. This item is printed on demand.
Lingua: Inglese
Editore: Elsevier Science & Technology, Academic Press, 2022
ISBN 10: 0128244852 ISBN 13: 9780128244852
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 136,05
Quantità: 2 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once 'undruggable? RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.